Formulations for amylin agonist peptides

Details Formulations for amylin agonist peptides Formulations for amylin agonist peptides

2007-12-25

2007-12-25

Channavajjala, Lakshmi S. (Department: 1615)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S003100, C514S004300, C514S866000, C514S864000, C424S400000, C530S324000

Reexamination Certificate

active

10159779

ABSTRACT:
The present invention is concerned with a pharmaceutical formulation comprising an amylin agonist and optionally a buffer, a tonicifier or stabilizer, and a preservative in a container, for example, a vial, prefilled cartridge, prefilled syringe or disposable pen. This formulation may be in liquid, gel, solid or powdered form for delivery, for example, via nasal, pulmonary, oral, sublingual, buccal, transdermal, or parenteral routes. Formulation with biocompatible polymers and release modifiers, such as sugars, can facilitate controlled release after injection, minimizing the number of administrations to a patient. These formulations maintain stability upon storage under refrigerated or room temperature conditions. Such formulations can be further combined with insulin for administration to a patient.

REFERENCES:
patent: 4654324 (1987-03-01), Chance et al.
patent: 5124314 (1992-06-01), Cooper
patent: 5175145 (1992-12-01), Cooper
patent: 5234906 (1993-08-01), Young et al.
patent: 5266561 (1993-11-01), Cooper et al.
patent: 5280014 (1994-01-01), Cooper et al.
patent: 5281581 (1994-01-01), Cooper et al.
patent: 5364841 (1994-11-01), Cooper et al.
patent: 5367052 (1994-11-01), Cooper et al.
patent: 5503827 (1996-04-01), Woog et al.
patent: 5508260 (1996-04-01), Beaumont
patent: 5686411 (1997-11-01), Gaeta et al.
patent: 5783556 (1998-07-01), Clark et al.
patent: 5791466 (1998-08-01), Tsals
patent: 6136784 (2000-10-01), LItalien et al.
patent: 6410511 (2002-06-01), L'Italien et al.
patent: WO 93/10146 (1993-05-01), None
patent: WO 96/40196 (1996-12-01), None
patent: WO 96/40220 (1998-12-01), None
patent: WO 98/55144 (1998-12-01), None
Ratner et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type I diabetes. U.S. study Group iof Insulin Glargine in Type I diabetes. Diabetes Care . May 2000, 23(5):639-643.
Zhou et al. Peptide and protein drugs:I. Therapeutic applications, absorption and parenteral administration. International Journal of Pharmaceutics, (1991), vol. 75, pp. 97-115.
Ratner et al. Les hypoglemia with insulin glargine in intensive insulin therapy for type I diabetes. U.S.Study group of insulin glargfine in Type I diabetes. Diabetes Care 2000. vol. 23 (5): pp. 576-578. abstract only.
Amylin Pharmaceuticals. “Amylin Pharmaceuticals Announces Positive Positive Clinical Results in Mixing Its Experimental Diabetes Drug with Insulin” Amylin Pharmaceuticals Press Release, San Diego, California (Jan. 8, 1997).
Arakawa et al. “Change in Solubility of Insulin in Therapeutic Mixtures of Insulin Preparations: HPLC Analysis” Diabetes Research and Clinical Practice 7:S93-S100 (1989).
Avis et al. (Ed.)Pharmaceutical Dosage Forms: Parenteral Medicationsvol. 1, 2ndEd., Mercel Dekker, New York, N.Y. (1992).
Brange et al. “Insulin Structure and Stability” in Stability and Characterization of Protein and Peptide Drugs: Case Histories (1993).
Colowick et al. (Eds.)Methods in Enzymologyvol. 1 Academic Press Inc., Publishers, NY pp. 13146 (1955).
Cooper et al. “Purification and Characterization of a Peptide from Amyloid-Rich Pancreases of Type 2 Diabetic Patients” Proceedings of the National Academy of Sciences USA 84(23):8628-8632 (1987).
Deshmukh et al. “Simulated Patient-Use Patterns and Temperature Excursion Studies on Pramlintide Injection Final Drug Product” Pharmaceutical Research 14 (11 Supp): S469-S470 (1997) (Abstract 3022).
Gaeta and Rink. “Amylin: A New Hormone as a Therapeutic Target in Diabetes Mellitus and Other Metabolic Diseases” Med. Chem. Res. 3:483-490 (1994).
Gennaro (Ed.)Remington's Pharmaceutical Sciences18thEd. Mack Publishing Co. pp. 1545-1553 (1990).
Hekman et al. “Isolation and Identification of Cyclic Imide and Deamidation Products in Heat Stress Pramlintide Injection Drug Product” J Pharm & Biomed Analysis 20(5):763-772 (1999).
Kenley et al. “Kinetics of Pramlintide Degradation in Aqueous Solution As a Function of Temperature and pH” AAPS Pharmscitech 1(2):article 7 (Apr. 21, 2000).
Kenley et al. “Pramlintide Injection Drug Product Robustness Studies” AAPS Pharmscitech 1(2):article 8 (Apr. 21, 2000).
Kolterman et al. “Effect of 14 Days' Subcutaneous Administration of the Human Amylin Analogue, Pramlintide (AC137), on an Intravenous Insulin Challenge and Response to a Standard Liquid Meal in Patients with IDDM” Diabetologia 39(4):492-499 (1996).
Leighton et al. “The Role of Amylin in the Insulin Resistance of Non-Insulin-Dependent Diabetes Mellitus” TIBS 15:295 (1990).
Manning et al. “Stability of Protein Pharmaceuticals” Pharmaceutical Research 6(11):903-918 (1989).
Mlodzik. “Oncologic, Endocrine & Metabolic Antidiabetes: Analysis of Patenting 1990-199” Exp. Opin Ther. Patents 5(7):685-688 (1995).
Pittner et al. “Molecular Physiology of Amylin” J. Cell Biochem. 55S:19-28 (1994).
Rink et al. “Structure and Biology of Amylin” TIPS 14:113-118 (1993).
Sifton (Ed.)Physician's Desk Reference50thEd. pp. 1797-1800 (1996).
Wang et al. “Parental Formulations of Proteins and Peptides: Stability and Stabilizers” J. Parenteral Science and Technology Supplement 42S:S4-S26 Technology Report No. 10 (1988).
Wang et al. “Review of Excipients and pH's for Parenteral Products Used in the United States” J. Parenteral Drug Assoc. 34:452 (1980).

Affiliated with

Also associated with

Rating

Formulations for amylin agonist peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Formulations for amylin agonist peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Formulations for amylin agonist peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3862720